Practice-Based Evidence: Profiling the Safety of Cilostazol by Text-Mining of Clinical Notes

BACKGROUND: Peripheral arterial disease (PAD) is a growing problem with few available therapies. Cilostazol is the only FDA-approved medication with a class I indication for intermittent claudication, but carries a black box warning due to concerns for increased cardiovascular mortality. To assess t...

Descripción completa

Detalles Bibliográficos
Autores principales: Leeper, Nicholas J., Bauer-Mehren, Anna, Iyer, Srinivasan V., LePendu, Paea, Olson, Cliff, Shah, Nigam H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662653/
https://www.ncbi.nlm.nih.gov/pubmed/23717437
http://dx.doi.org/10.1371/journal.pone.0063499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662653/
https://www.ncbi.nlm.nih.gov/pubmed/23717437
http://dx.doi.org/10.1371/journal.pone.0063499

Ejemplares similares